PGGM Investments Sells 1,687 Shares of DaVita Inc. (NYSE:DVA)

PGGM Investments reduced its position in shares of DaVita Inc. (NYSE:DVA) by 19.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,187 shares of the company’s stock after selling 1,687 shares during the period. PGGM Investments’ holdings in DaVita were worth $753,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Czech National Bank boosted its position in shares of DaVita by 43.7% during the 3rd quarter. Czech National Bank now owns 9,412 shares of the company’s stock valued at $890,000 after acquiring an additional 2,863 shares during the last quarter. Asset Management One Co. Ltd. grew its stake in DaVita by 3.2% in the 3rd quarter. Asset Management One Co. Ltd. now owns 21,759 shares of the company’s stock worth $2,057,000 after buying an additional 672 shares in the last quarter. Handelsbanken Fonder AB raised its position in shares of DaVita by 21.2% during the 3rd quarter. Handelsbanken Fonder AB now owns 8,000 shares of the company’s stock valued at $756,000 after buying an additional 1,400 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its holdings in shares of DaVita by 175.4% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 50,343 shares of the company’s stock worth $4,759,000 after acquiring an additional 32,062 shares during the last quarter. Finally, Xponance Inc. grew its position in DaVita by 86.1% in the third quarter. Xponance Inc. now owns 27,382 shares of the company’s stock worth $2,588,000 after acquiring an additional 12,670 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Price Performance

DVA opened at $138.14 on Tuesday. The company has a debt-to-equity ratio of 6.65, a current ratio of 1.19 and a quick ratio of 1.13. DaVita Inc. has a 1 year low of $71.51 and a 1 year high of $141.54. The stock’s 50 day simple moving average is $132.44 and its 200 day simple moving average is $111.30. The firm has a market cap of $12.11 billion, a price-to-earnings ratio of 18.67, a PEG ratio of 1.19 and a beta of 1.04.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, February 13th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.53 by $0.34. The company had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.01 billion. DaVita had a net margin of 5.70% and a return on equity of 64.42%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the business posted $1.11 EPS. As a group, analysts predict that DaVita Inc. will post 9.23 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on DVA shares. Barclays initiated coverage on DaVita in a research report on Wednesday, March 6th. They set an “equal weight” rating and a $133.00 price target on the stock. TheStreet raised DaVita from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. UBS Group increased their price target on shares of DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Truist Financial boosted their price objective on shares of DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a report on Tuesday, February 20th. Finally, StockNews.com raised shares of DaVita from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 25th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.50.

Insiders Place Their Bets

In related news, CEO Javier Rodriguez sold 67,603 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the sale, the chief executive officer now owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, COO Michael David Staffieri sold 29,488 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $119.81, for a total transaction of $3,532,957.28. Following the completion of the transaction, the chief operating officer now owns 37,687 shares of the company’s stock, valued at approximately $4,515,279.47. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Javier Rodriguez sold 67,603 shares of the firm’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $126.11, for a total value of $8,525,414.33. Following the transaction, the chief executive officer now owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The disclosure for this sale can be found here. In the last 90 days, insiders sold 134,540 shares of company stock worth $16,551,071. 1.40% of the stock is currently owned by company insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.